The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
RNA Interference (RNAi) Drug Delivery-Global Market Insights and Sales Trends 2025
Synopsis
The global RNA Interference (RNAi) Drug Delivery market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of RNA Interference (RNAi) Drug Delivery in various end use industries. The expanding demands from the Infectious Diseases, Cardiology, Oncology and Neurology, are propelling RNA Interference (RNAi) Drug Delivery market. Nanoparticle Drug Delivery Technology, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pulmonary Drug Delivery Technology segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for RNA Interference (RNAi) Drug Delivery, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global RNA Interference (RNAi) Drug Delivery market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global RNA Interference (RNAi) Drug Delivery market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, RNA Interference (RNAi) Drug Delivery sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of RNA Interference (RNAi) Drug Delivery covered in this report include Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp and Quark Pharmaceuticals Inc, etc.
The global RNA Interference (RNAi) Drug Delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
Global RNA Interference (RNAi) Drug Delivery market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global RNA Interference (RNAi) Drug Delivery market, Segment by Type:
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Global RNA Interference (RNAi) Drug Delivery market, by Application
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of RNA Interference (RNAi) Drug Delivery manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of RNA Interference (RNAi) Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global RNA Interference (RNAi) Drug Delivery market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of RNA Interference (RNAi) Drug Delivery in various end use industries. The expanding demands from the Infectious Diseases, Cardiology, Oncology and Neurology, are propelling RNA Interference (RNAi) Drug Delivery market. Nanoparticle Drug Delivery Technology, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pulmonary Drug Delivery Technology segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for RNA Interference (RNAi) Drug Delivery, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global RNA Interference (RNAi) Drug Delivery market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global RNA Interference (RNAi) Drug Delivery market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, RNA Interference (RNAi) Drug Delivery sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of RNA Interference (RNAi) Drug Delivery covered in this report include Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp and Quark Pharmaceuticals Inc, etc.
The global RNA Interference (RNAi) Drug Delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
Global RNA Interference (RNAi) Drug Delivery market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global RNA Interference (RNAi) Drug Delivery market, Segment by Type:
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Global RNA Interference (RNAi) Drug Delivery market, by Application
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of RNA Interference (RNAi) Drug Delivery manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of RNA Interference (RNAi) Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 RNA Interference (RNAi) Drug Delivery Market Overview
1.1 RNA Interference (RNAi) Drug Delivery Product Overview
1.2 RNA Interference (RNAi) Drug Delivery Market Segment by Type
1.2.1 Nanoparticle Drug Delivery Technology
1.2.2 Pulmonary Drug Delivery Technology
1.2.3 Nucleic Acid Drug Delivery Technology
1.2.4 Aptamer Drug Delivery Technology
1.3 Global RNA Interference (RNAi) Drug Delivery Market Size by Type
1.3.1 Global RNA Interference (RNAi) Drug Delivery Market Size Overview by Type (2018-2029)
1.3.2 Global RNA Interference (RNAi) Drug Delivery Historic Market Size Review by Type (2018-2023)
1.3.3 Global RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America RNA Interference (RNAi) Drug Delivery Sales Breakdown by Type (2018-2023)
1.4.2 Europe RNA Interference (RNAi) Drug Delivery Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales Breakdown by Type (2018-2023)
1.4.4 Latin America RNA Interference (RNAi) Drug Delivery Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales Breakdown by Type (2018-2023)
2 Global RNA Interference (RNAi) Drug Delivery Market Competition by Company
2.1 Global Top Players by RNA Interference (RNAi) Drug Delivery Sales (2018-2023)
2.2 Global Top Players by RNA Interference (RNAi) Drug Delivery Revenue (2018-2023)
2.3 Global Top Players by RNA Interference (RNAi) Drug Delivery Price (2018-2023)
2.4 Global Top Manufacturers RNA Interference (RNAi) Drug Delivery Manufacturing Base Distribution, Sales Area, Product Type
2.5 RNA Interference (RNAi) Drug Delivery Market Competitive Situation and Trends
2.5.1 RNA Interference (RNAi) Drug Delivery Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by RNA Interference (RNAi) Drug Delivery Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in RNA Interference (RNAi) Drug Delivery as of 2022)
2.7 Date of Key Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market
2.8 Key Manufacturers RNA Interference (RNAi) Drug Delivery Product Offered
2.9 Mergers & Acquisitions, Expansion
3 RNA Interference (RNAi) Drug Delivery Status and Outlook by Region
3.1 Global RNA Interference (RNAi) Drug Delivery Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global RNA Interference (RNAi) Drug Delivery Historic Market Size by Region
3.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2018-2023)
3.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2018-2023)
3.2.3 Global RNA Interference (RNAi) Drug Delivery Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Region
3.3.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2024-2029)
3.3.2 Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2024-2029)
3.3.3 Global RNA Interference (RNAi) Drug Delivery Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global RNA Interference (RNAi) Drug Delivery by Application
4.1 RNA Interference (RNAi) Drug Delivery Market Segment by Application
4.1.1 Infectious Diseases
4.1.2 Cardiology
4.1.3 Oncology
4.1.4 Neurology
4.1.5 Ophthalmology
4.1.6 Metabolic Disorders
4.2 Global RNA Interference (RNAi) Drug Delivery Market Size by Application
4.2.1 Global RNA Interference (RNAi) Drug Delivery Market Size Overview by Application (2018-2029)
4.2.2 Global RNA Interference (RNAi) Drug Delivery Historic Market Size Review by Application (2018-2023)
4.2.3 Global RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America RNA Interference (RNAi) Drug Delivery Sales Breakdown by Application (2018-2023)
4.3.2 Europe RNA Interference (RNAi) Drug Delivery Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales Breakdown by Application (2018-2023)
4.3.4 Latin America RNA Interference (RNAi) Drug Delivery Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales Breakdown by Application (2018-2023)
5 North America RNA Interference (RNAi) Drug Delivery by Country
5.1 North America RNA Interference (RNAi) Drug Delivery Historic Market Size by Country
5.1.1 North America RNA Interference (RNAi) Drug Delivery Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2018-2023)
5.1.3 North America RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2018-2023)
5.2 North America RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Country
5.2.1 North America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2024-2029)
5.2.2 North America RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2024-2029)
6 Europe RNA Interference (RNAi) Drug Delivery by Country
6.1 Europe RNA Interference (RNAi) Drug Delivery Historic Market Size by Country
6.1.1 Europe RNA Interference (RNAi) Drug Delivery Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2018-2023)
6.1.3 Europe RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2018-2023)
6.2 Europe RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Country
6.2.1 Europe RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2024-2029)
6.2.2 Europe RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2024-2029)
7 Asia-Pacific RNA Interference (RNAi) Drug Delivery by Region
7.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Historic Market Size by Region
7.1.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2018-2023)
7.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Region
7.2.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2024-2029)
8 Latin America RNA Interference (RNAi) Drug Delivery by Country
8.1 Latin America RNA Interference (RNAi) Drug Delivery Historic Market Size by Country
8.1.1 Latin America RNA Interference (RNAi) Drug Delivery Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2018-2023)
8.1.3 Latin America RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2018-2023)
8.2 Latin America RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Country
8.2.1 Latin America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2024-2029)
8.2.2 Latin America RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2024-2029)
9 Middle East and Africa RNA Interference (RNAi) Drug Delivery by Country
9.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Historic Market Size by Country
9.1.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2018-2023)
9.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Forecasted Market Size by Country
9.2.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Metabolic disorders
10.1.1 Metabolic disorders Company Information
10.1.2 Metabolic disorders Introduction and Business Overview
10.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Metabolic disorders RNA Interference (RNAi) Drug Delivery Products Offered
10.1.5 Metabolic disorders Recent Development
10.2 Alnylam Pharmaceuticals Inc
10.2.1 Alnylam Pharmaceuticals Inc Company Information
10.2.2 Alnylam Pharmaceuticals Inc Introduction and Business Overview
10.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.2.5 Alnylam Pharmaceuticals Inc Recent Development
10.3 Merck & Co. Inc
10.3.1 Merck & Co. Inc Company Information
10.3.2 Merck & Co. Inc Introduction and Business Overview
10.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.3.5 Merck & Co. Inc Recent Development
10.4 Access Pharmaceuticals Inc
10.4.1 Access Pharmaceuticals Inc Company Information
10.4.2 Access Pharmaceuticals Inc Introduction and Business Overview
10.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.4.5 Access Pharmaceuticals Inc Recent Development
10.5 Dicerna Pharmaceuticals Inc
10.5.1 Dicerna Pharmaceuticals Inc Company Information
10.5.2 Dicerna Pharmaceuticals Inc Introduction and Business Overview
10.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.5.5 Dicerna Pharmaceuticals Inc Recent Development
10.6 Calondo Pharmaceuticals Inc
10.6.1 Calondo Pharmaceuticals Inc Company Information
10.6.2 Calondo Pharmaceuticals Inc Introduction and Business Overview
10.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.6.5 Calondo Pharmaceuticals Inc Recent Development
10.7 Marina Biotech Inc
10.7.1 Marina Biotech Inc Company Information
10.7.2 Marina Biotech Inc Introduction and Business Overview
10.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.7.5 Marina Biotech Inc Recent Development
10.8 RXi Pharmaceuticals Corp
10.8.1 RXi Pharmaceuticals Corp Company Information
10.8.2 RXi Pharmaceuticals Corp Introduction and Business Overview
10.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.8.4 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Products Offered
10.8.5 RXi Pharmaceuticals Corp Recent Development
10.9 Quark Pharmaceuticals Inc
10.9.1 Quark Pharmaceuticals Inc Company Information
10.9.2 Quark Pharmaceuticals Inc Introduction and Business Overview
10.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.9.5 Quark Pharmaceuticals Inc Recent Development
10.10 Silence Therapeutics plc
10.10.1 Silence Therapeutics plc Company Information
10.10.2 Silence Therapeutics plc Introduction and Business Overview
10.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Products Offered
10.10.5 Silence Therapeutics plc Recent Development
10.11 Tacere Therapeutics Inc
10.11.1 Tacere Therapeutics Inc Company Information
10.11.2 Tacere Therapeutics Inc Introduction and Business Overview
10.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.11.5 Tacere Therapeutics Inc Recent Development
10.12 PhaseRx Inc
10.12.1 PhaseRx Inc Company Information
10.12.2 PhaseRx Inc Introduction and Business Overview
10.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.12.4 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.12.5 PhaseRx Inc Recent Development
10.13 Sirnaomics Inc
10.13.1 Sirnaomics Inc Company Information
10.13.2 Sirnaomics Inc Introduction and Business Overview
10.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.13.5 Sirnaomics Inc Recent Development
10.14 Traversa Therapeutics Inc
10.14.1 Traversa Therapeutics Inc Company Information
10.14.2 Traversa Therapeutics Inc Introduction and Business Overview
10.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Products Offered
10.14.5 Traversa Therapeutics Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 RNA Interference (RNAi) Drug Delivery Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 RNA Interference (RNAi) Drug Delivery Industrial Chain Analysis
11.4 RNA Interference (RNAi) Drug Delivery Market Dynamics
11.4.1 RNA Interference (RNAi) Drug Delivery Industry Trends
11.4.2 RNA Interference (RNAi) Drug Delivery Market Drivers
11.4.3 RNA Interference (RNAi) Drug Delivery Market Challenges
11.4.4 RNA Interference (RNAi) Drug Delivery Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 RNA Interference (RNAi) Drug Delivery Distributors
12.3 RNA Interference (RNAi) Drug Delivery Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
